fda compounding semaglutide enforcement october 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our Novo Nordisk expands legal action

Whether youre on your first shot or your fifteenth, understanding your B12 form matters

For some women, the right approach might even involve combining medications

Amniotic vascular endothelial growth factor (VEGF) and nitric oxide (NO) in women with subsequent preeclampsia

Here are three of our most popular options: Our most in-demand treatment, Semaglutide is a powerful GLP-1 medication that works by reducing appetite, improving blood sugar control, and helping you feel fuller longer

These medications work by inhibiting glucose reabsorption in the renal proximal tubule, promoting urinary glucose excretion

When you're dealing with chronic pain or a slow-healing injury, the promise of rapid recovery can be incredibly tempting